Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

Alectinib is a standard initial treatment for patients with advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). The current study analyzed a prospective cohort of 24 consecutive alectinib-treated patients and controls in order to comprehensively characterize long...

Full description

Bibliographic Details
Main Authors: Julia Kunz, Christiane Wiedemann, Heidrun Grosch, Katharina Kriegsmann, Stefanie Gryzik, Julia Felden, Michael Hundemer, Huriye Seker-Cin, Miriam Stenzinger, Albrecht Leo, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
ALK+ NSCLC
alectinib
anemia
hemolysis
acanthocytosis
Online Access:https://www.mdpi.com/2072-6694/14/11/2720

Internet

https://www.mdpi.com/2072-6694/14/11/2720

Similar Items